Endurance
Engineered for maximum wear time.
Confidence
Never lose a device.
Freedom
Skin Grip moves with you, never against you.
SHOP BESTSELLERS
Skin Grip Original - Dexcom G6 Patches
Choose your option
Skin Grip MAX Dexcom G6 Patches - 10 Pack
Choose your option
Skin Grip Original - Medtronic Guardian/Enlite Adhesive Patches
Choose your option
Skin Grip Original - Freestyle Libre 2+ & Lingo Adhesive Patches
Choose your option
Skin Grip MAX Dexcom G7 & Stelo Patches - 10 Pack
Choose your option
Skin Grip Original - Dexcom G7 & Stelo Adhesive Patches (With Cutout)
Choose your option
Skin Grip Original - Omnipod Adhesive Patches
Choose your option
Skin Grip Original - Dexcom G7 & Stelo Adhesive Patches
Choose your option
Skin Grip - Tandem Mobi Pocket Patch
Choose your option
Sensors Saved
Trusted By
Say Goodbye To
Sensor Failure Mid-Routine
Adhesion built to last through motion, sweat, and time.
Manufacturer Replacements on Repeat
Designed for reliability — not replacements.
Waiting on New Sensors to Arrive
Every patch extends your wear. Every day counts.
Losing a Reading When Life Gets Close
Holds steady through hugs, heat, and high impact.
Returning to Fingerpricks and Frustration
Performance that stays put. Confidence that stays on.
→ Built to grip. Made to stay.
DIABETES MANAGEMENT
Your go-to hub for tips, tricks, and real talk on living boldly with diabetes
Dexcom vs Libre: What’s the Difference Between These CGMs?
If you wear a CGM, chances are you’ve wondered at some point: would the other one work better for me? Maybe your sensor doesn’t always last the full wear time, alerts feel overwhelming, or you’re curious about features you’ve heard other people talk about. Dexcom and FreeStyle Libre 3+ are two of the most widely used CGM systems, and both have their respective pros and cons list. While they ultimately serve the same purpose, the experience of wearing them day to day can feel quite different depending on things like wear time, alerts, integrations, and how they fit into your overall tech setup. In this guide, we’ll break down the practical differences between Dexcom and Libre so you can better understand what each system offers and why some people prefer one over the other. What Dexcom and Libre Have in Common At a basic level, Dexcom and Libre systems do the same thing: they continuously measure glucose levels through a small sensor worn on the body and send those readings to a smartphone or receiver. Both systems: Track glucose trends throughout the day Display readings on a mobile app Allow data sharing with caregivers or family members Reduce the need for frequent fingerstick testing They’re also both small and discreet, roughly the size of stacked coins, and worn on the skin for multiple days at a time. Dexcom CGM Systems Dexcom’s newest CGM is the Dexcom G7, their smallest CGM yet that will replace all G6 sensors after the announced discontinuation in July of 2026. Key features Wear time: 10 days or 15 days depending on the version, plus a 12 hour grace period Warm-up time: 30 minutes Glucose readings: every 5 minutes Alerts: customizable high, low, and predictive alerts Data sharing: Dexcom Follow allows up to 10 followers Integrations: Omnipod 5, Tandem t:slim X2, Tandem Mobi, and Beta Bionics iLet Bionic Pancreas One of Dexcom’s biggest strengths is device integration. Because of the wide variety of choice, Dexcom is often the CGM used in hybrid closed-loop pump systems. FreeStyle Libre CGM Systems Abbott’s FreeStyle Libre family has become one of the most widely used CGM platforms globally. The latest version compatible with closed loop systems is FreeStyle Libre 3+. Key features Wear time: 15 days Warm-up time: 60 minutes Glucose readings: every minute Very small sensor: one of the smallest CGM sensors available Data sharing: LibreLinkUp allows data sharing with up to 20 followers Integrations: Tandem t:slim X2, Beta Bionics iLet Bionic Pancreas, Sequel Med Tech twiist, and a Limited Market Release with Omnipod 5 Libre 3+ sensors is known for its long wear time and small profile, which many users find comfortable and discreet. Key Differences at a Glance Feature Dexcom G7 FreeStyle Libre 3+ Wear time ~10 days or 15 days (+12-hour grace period) ~15 days Warm-up time ~30 minutes ~60 minutes Glucose readings Every 5 minutes Every minute Sensor size 27mm x 23mm x 4.7mm 21mm x 2.9 mm Both systems are highly accurate and widely used, but the experience can feel different depending on what matters most to you. Which CGM Might Fit Your Lifestyle? Different people prioritize different things when choosing diabetes tech. Dexcom G7 may appeal to people who: Use (or want) an automated insulin delivery system Want predictive alerts for low glucose Prefer deeper integration with pumps and apps Libre 3+ may appeal to people who: Prefer longer sensor wear time Want a very small, discreet sensor Like a simple, streamlined CGM experience Ultimately, both systems provide valuable real-time glucose data that can help people understand patterns and make more informed decisions about their diabetes care. The Bottom Line Dexcom and FreeStyle Libre are two of the most advanced CGM platforms available today. Both offer powerful tools for understanding glucose trends, reducing fingersticks, and improving daily awareness. The right option often comes down to lifestyle preferences, device compatibility, and insurance coverage. No matter which system you use, the goal is the same: helping you stay informed, confident, and supported in your daily life with diabetes.
Read more
The Future of Patch Pumps: What’s next for tubeless insulin delivery in 2026 and beyond
Patch pumps have already changed the game for a lot of people with diabetes: no tubing, fewer “where do I clip this?” moments, and a setup that can feel more streamlined for daily life. What’s ahead looks even more interesting - companies are pushing for longer wear, bigger reservoirs, smarter automation, and more flexible ecosystems. Below is a forward-looking roundup of four patch-pump pipelines to watch: Tandem’s tubeless Mobi concept, Beta Bionics’ Mint, Medtronic’s MiniMed Fit, and Insulet’s Omnipod 6. (Heads up: future features and dates can change based on FDA review, clinical testing, and manufacturing timelines). 1) Tandem’s tubeless Mobi: a patch-pump direction for a familiar ecosystem Tandem has been very open that it’s working toward patch-pump options, including a pathway that would transform Mobi into a tubeless patch device via a novel extended-wear infusion site. Tandem also says a next-generation Mobi patch pump is in its pipeline, leveraging technology from its Sigi acquisition. What to watch for Extended wear: Public reporting links Tandem’s SteadiSet (extended-wear infusion set) with the broader push toward longer-wear pump sites. Timeline: Tandem has not pinned a firm consumer launch date for its tubeless Mobi patch device on its public innovations page, but extended-wear components and development milestones are being discussed in 2026-oriented roadmaps. Why it matters: If a Mobi-based patch approach arrives, it could offer a new middle lane between traditional tubed pumps and disposable pods, especially for people who want the flexibility of a patch form factor but prefer a Tandem ecosystem. 2) Beta Bionics Mint: a fresh patch pump with a different philosophy Beta Bionics made waves discussing Mint, its in-development patch pump. Reporting from ADA coverage describes Mint as a 3-day patch pump that holds up to 200 units, with a concept that includes a reusable controller and phone compatibility. What to watch for Wear time & capacity: ~3 days and ~200 units puts it in familiar pod territory Timing: Beta Bionics has indicated a 2027 window for launch, echoed by analyst coverage and earnings call commentary. Why it matters: Competition is good. More patch-pump options means more chances for people to find the setup that fits their preferences, budget, and lifestyle. 3) Medtronic MiniMed Fit: bigger reservoir + longer wear ambitions Medtronic’s MiniMed Fit is one of the most concrete next wave patch pumps on the horizon in terms of reported specs: coverage has repeatedly pointed to ~300 units and ~7-day wear. This is a notable shift as many current pod users are used to ~3 days. What to watch for FDA timing: Medtronic has said it intends to submit Fit to the FDA by fall 2026. Development activity: ClinicalTrials.gov includes a Medtronic study referencing 7-day wear adhesive components for the MiniMed Fit payload, one more public signal that development is actively moving forward. Launch window: Multiple reports suggest market availability likely no earlier than 2027, though timelines can shift. Why it matters: If Fit lands with a true 7-day patch wear experience and a 300-unit reservoir, it could be a major quality-of-life upgrade for people who want fewer change days. 4) Omnipod 6: next-gen evolution of the category leader Insulet has publicly outlined a roadmap that includes Omnipod 6 and has pointed to 2027 as the target launch window. What to watch for Ecosystem upgrades: Insulet has also talked about enhancing the Omnipod 5 ecosystem in 2026 (pending FDA clearance), including broader connectivity and deeper insights, signaling that Omnipod’s software layer and integrations remain a key focus as Omnipod 6 approaches. Wear time & reservoir: Insulet’s core platform messaging still emphasizes “up to three days” of insulin delivery for Omnipod pods. Until Insulet publishes exact Omnipod 6 hardware specs, it’s safest to assume the next-gen system may keep the same form factor. What’s new: Reporting around Investor Day suggests meaningful algorithm and system improvements are part of the Omnipod 6 story. Why it matters: Omnipod has defined the patch pump category for years. Omnipod 6 will likely set the tone for what “baseline expectations” become, especially around automation, connectivity, and user experience. The bottom line: 2026 is about momentum, 2027 looks like a turning point If you zoom out, the direction is clear: longer wear, bigger reservoirs, and smarter systems that fit more naturally into daily life. With big names signaling patch pump roadmaps and multiple products converging on a 2027 window, the future of patch pumps is less a distant concept and more a pipeline that’s actively taking shape. Quick disclaimer Details for in-development devices can change quickly. Always confirm final specs (wear time, reservoir size, CGM compatibility, phone control, waterproofing) on the manufacturer’s site once products are FDA-cleared and commercially released.
Read more
What's Coming in Diabetes Tech in 2026
Diabetes technology never stands still. Every year brings new tools that can make life with diabetes a little easier, more predictable, and more connected. In 2026, the pace of innovation continues to accelerate. From smarter algorithms and longer-wear sensors to novel integration and early-stage breakthroughs, there's a lot to look forward to. Here’s what’s on the horizon for diabetes tech in 2026. Insulin Delivery Systems & Upcoming Models Tandem Diabetes Care — Patch Pumps & Tubeless Mobi Tandem has already integrated its t:slim X2 and Mobi systems with Dexcom sensors and is working on a tubeless patch pump version of the Mobi. This future iteration is expected to offer up to a 7-day wear time using the SteadiSet infusion set and wireless charging. Tandem is also expanding sensor support — including Dexcom G7 and Abbott FreeStyle Libre 3 Plus, with early access programs and broader rollout planned. Why it’s exciting: Patch pump form factor bridges traditional tubed pumps and disposable pods Longer wear and wireless charging improve convenience More sensor compatibility increases flexibility Medtronic — MiniMed “8-Series” & Patch Pump Concepts Medtronic is preparing to submit its next insulin pump platform — the MiniMed 8-series — with a smaller, streamlined design that may not have a built-in screen, instead relying on smartphone control. They’ve also shown early versions of a patch pump prototype with a 300-unit reservoir and ~7-day wear potential. What to watch: Larger reservoir and longer wear than many current systems Phone-first control instead of traditional pump hardware Integration with Medtronic’s Simplera glucose sensor and potential Libre compatibility Beta Bionics — iLet & “Mint” Patch Pump Prototype Beta Bionics is already on the market with its iLet Bionic Pancreas (ACE Pump), which pairs with Dexcom and FreeStyle Libre 3 Plus CGMs and automates insulin delivery using multiple built-in algorithms. The company also previewed a reusable patch pump prototype (“Mint”) that could cut down on disposable parts while keeping an automated delivery engine. Why it’s a key company: The iLet’s algorithm reduces need for manual basal programming “Mint” could bring a new patch option to the automated pump category Insulet — Omnipod 5 & Future Omnipod 6 Insulet’s Omnipod 5 remains one of the most widely used patch pumps, integrating with Dexcom and FreeStyle Libre 2 Plus CGMs directly and offering SmartAdjust automated insulin delivery. Insulet is continuing to evolve the platform, with community buzz around advancements often referred to as Omnipod 6 (though specifics aren’t fully public yet). What makes it stand out: Pod-based, tubeless AID system many users love for flexibility Upcoming whatever-next-gen improvements are expected to refine wearability and features Next-Gen Sensors & Monitoring Tech Dexcom — G7 with Extended Wear & Apple Watch Connectivity Dexcom’s newest CGM this year included the G7 15-Day wearable, building on extended wear approvals and direct connectivity to smartwatches (like Apple Watch) without needing a phone as an intermediary. This matters because: Extended wear reduces sensor changes Native wrist access increases accessibility for fast checks Multi-Analyte CGMs in Development (Abbott & Others) Abbott is advancing multi-analyte sensors that aim to measure glucose plus ketones (not just a single glucose value) which could give earlier indicators of metabolic states before numbers swing widely. Why to watch: Ketones alongside glucose could mean earlier warnings for DKA risk Multi-data sensors open doors for richer self-management insights Software, Algorithms & Integration Advances twiist AID Platform (Sequel Med Tech) The twiist AID system is gearing up for wider release with multiple algorithm options, including both Loop-based and commercial FDA-cleared choices, offering flexibility and personal customization. What’s notable: Users can choose algorithm styles that suit their lifestyle or management goals Supports interoperability with common CGMs Beyond Hardware — AI and Pattern Recognition Tech at diabetes conferences this year emphasized AI-driven insights and pattern recognition, including forecasting tools and smarter software that makes sense of CGM trends without manual interpretation. Researchers are working on models that could help predict glucose levels with machine-driven context analysis beyond raw numbers. Big picture trend: Smarter software could reduce cognitive load Prep for tools that make sense of data instead of just showing it Quick Summary — Tech to Watch in 2026 Tandem: Tubeless patch pump with extended wear & wireless features Medtronic: MiniMed 8-series & patch pump concepts with larger reservoirs Beta Bionics: iLet automated system + reusable patch prototype Insulet: Ongoing Omnipod evolution (Omnipod 5 → Omnipod 6) Dexcom: G7 extended wear & watch connectivity expansions Abbott / Sensor Innovators: Multi-analyte CGM development Sequel Med Tech: twiist algorithm options for personalized AID What It All Means 2026 is shaping up less to be about one big breakthrough and more about smarter, more flexible tech ecosystems that give people choice — from how they wear pumps to how their CGMs interpret metabolic states, and how algorithms adapt to individual needs. New patch pump designs, smarter algorithms, sensor innovations, and expanded integration will keep pushing diabetes tech into everyday life — making it feel less like tech to manage and more like tech that supports life.
Read more
